King Luther Capital Management Corp Buys 17,781 Shares of Charles River Laboratories International, Inc. $CRL

King Luther Capital Management Corp boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 37.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,761 shares of the medical research company’s stock after purchasing an additional 17,781 shares during the period. King Luther Capital Management Corp owned about 0.13% of Charles River Laboratories International worth $12,919,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cooke & Bieler LP lifted its stake in Charles River Laboratories International by 0.6% in the 4th quarter. Cooke & Bieler LP now owns 607,565 shares of the medical research company’s stock valued at $121,197,000 after purchasing an additional 3,688 shares during the last quarter. Prospera Financial Services Inc bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $382,000. LSV Asset Management lifted its stake in Charles River Laboratories International by 59.8% in the 4th quarter. LSV Asset Management now owns 475,900 shares of the medical research company’s stock valued at $94,933,000 after purchasing an additional 178,100 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Charles River Laboratories International by 3,385.2% in the 4th quarter. Global Retirement Partners LLC now owns 1,882 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 1,828 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Charles River Laboratories International by 1.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the medical research company’s stock valued at $3,203,000 after purchasing an additional 301 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL stock opened at $164.56 on Thursday. The company has a fifty day moving average price of $168.04 and a 200-day moving average price of $181.10. The company has a market capitalization of $7.93 billion, a P/E ratio of -43.77, a PEG ratio of 1.79 and a beta of 1.44. Charles River Laboratories International, Inc. has a 52-week low of $132.58 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on CRL. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Evercore reaffirmed an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. TD Cowen dropped their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $207.69.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.